MX2015008520A - 4-hidroxi-2-metil-5(propan-2-ilideno)ciclohex-3-enocarbaldehido para la prevencion y tratamiento de una enfermedad cognitiva, neurodegenerativa o neuronal. - Google Patents
4-hidroxi-2-metil-5(propan-2-ilideno)ciclohex-3-enocarbaldehido para la prevencion y tratamiento de una enfermedad cognitiva, neurodegenerativa o neuronal.Info
- Publication number
- MX2015008520A MX2015008520A MX2015008520A MX2015008520A MX2015008520A MX 2015008520 A MX2015008520 A MX 2015008520A MX 2015008520 A MX2015008520 A MX 2015008520A MX 2015008520 A MX2015008520 A MX 2015008520A MX 2015008520 A MX2015008520 A MX 2015008520A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative
- cognitive
- prevention
- treatment
- enecarbaldehyde
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001149 cognitive effect Effects 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- NESSRRDBNBBGEK-UHFFFAOYSA-N 4-hydroxy-2-methyl-5-propan-2-ylidenecyclohex-3-ene-1-carbaldehyde Chemical compound CC1C=C(O)C(=C(C)C)CC1C=O NESSRRDBNBBGEK-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un compuesto farmacéutico que tiene la Fórmula (1): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, para su uso en la prevención o el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales tal como la enfermedad de Alzheimer, una composición farmacéutica y un método de preparación de una composición farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92126A LU92126B1 (fr) | 2012-12-31 | 2012-12-31 | Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale |
| PCT/EP2013/076936 WO2014102090A1 (en) | 2012-12-31 | 2013-12-17 | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008520A true MX2015008520A (es) | 2015-09-10 |
| MX369590B MX369590B (es) | 2019-11-13 |
Family
ID=47470067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008520A MX369590B (es) | 2012-12-31 | 2013-12-17 | 4-hidroxi-2-metil-5(propan-2-ilideno)ciclohex-3-enocarbaldehido para la prevencion y tratamiento de una enfermedad cognitiva, neurodegenerativa o neuronal. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9284250B2 (es) |
| EP (1) | EP2938337A1 (es) |
| JP (1) | JP6699961B2 (es) |
| KR (1) | KR102104155B1 (es) |
| CN (1) | CN104884052B (es) |
| AR (1) | AR094318A1 (es) |
| AU (1) | AU2013369491B2 (es) |
| BR (1) | BR112015015509B1 (es) |
| CA (1) | CA2895429C (es) |
| CL (1) | CL2015001881A1 (es) |
| EA (1) | EA029650B1 (es) |
| HK (1) | HK1214517A1 (es) |
| IL (1) | IL239622B (es) |
| JO (1) | JO3483B1 (es) |
| LU (1) | LU92126B1 (es) |
| MA (1) | MA38307B1 (es) |
| MX (1) | MX369590B (es) |
| MY (1) | MY171832A (es) |
| NZ (1) | NZ710131A (es) |
| PE (1) | PE20151424A1 (es) |
| PH (1) | PH12015501402B1 (es) |
| SG (1) | SG11201504744WA (es) |
| TN (1) | TN2015000275A1 (es) |
| TW (1) | TWI590819B (es) |
| UA (1) | UA117822C2 (es) |
| UY (1) | UY35253A (es) |
| WO (1) | WO2014102090A1 (es) |
| ZA (1) | ZA201505057B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102788773B1 (ko) | 2012-12-21 | 2025-03-28 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
| US11434468B2 (en) * | 2017-01-13 | 2022-09-06 | Bened Biomedical Co., Ltd. | Lactic acid bacteria and its applications |
| KR102017415B1 (ko) * | 2018-02-13 | 2019-09-02 | 연세대학교 산학협력단 | 뇌 신경 손상 완화용 조성물 |
| CN108813453A (zh) * | 2018-05-23 | 2018-11-16 | 青岛大学 | 一种防治帕金森病的食用组合物 |
| BR112022010141A2 (pt) | 2019-12-02 | 2022-08-09 | Philip Morris Products Sa | Dispositivo shisha com calha |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000238755A1 (en) * | 2000-03-10 | 2001-09-24 | Applied Genetics Incorporated Dermatics | Dermatological compounds |
| CN1511520A (zh) * | 2002-12-31 | 2004-07-14 | �й�ҽѧ��ѧԺҩ���о��� | 丁二酸酯衍生物治疗痴呆症的用途 |
| WO2004080459A1 (en) * | 2003-03-14 | 2004-09-23 | Merck Sharp & Dohme Limited | Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease |
-
2012
- 2012-12-31 LU LU92126A patent/LU92126B1/fr active
-
2013
- 2013-12-17 US US14/758,343 patent/US9284250B2/en active Active
- 2013-12-17 BR BR112015015509-0A patent/BR112015015509B1/pt active IP Right Grant
- 2013-12-17 KR KR1020157020805A patent/KR102104155B1/ko active Active
- 2013-12-17 AU AU2013369491A patent/AU2013369491B2/en active Active
- 2013-12-17 CN CN201380069044.3A patent/CN104884052B/zh active Active
- 2013-12-17 EP EP13808014.8A patent/EP2938337A1/en not_active Ceased
- 2013-12-17 CA CA2895429A patent/CA2895429C/en active Active
- 2013-12-17 WO PCT/EP2013/076936 patent/WO2014102090A1/en active Application Filing
- 2013-12-17 HK HK16102495.8A patent/HK1214517A1/zh unknown
- 2013-12-17 NZ NZ710131A patent/NZ710131A/en unknown
- 2013-12-17 MX MX2015008520A patent/MX369590B/es active IP Right Grant
- 2013-12-17 JP JP2015550024A patent/JP6699961B2/ja active Active
- 2013-12-17 UA UAA201507037A patent/UA117822C2/uk unknown
- 2013-12-17 MY MYPI2015702083A patent/MY171832A/en unknown
- 2013-12-17 PE PE2015001180A patent/PE20151424A1/es unknown
- 2013-12-17 SG SG11201504744WA patent/SG11201504744WA/en unknown
- 2013-12-17 MA MA38307A patent/MA38307B1/fr unknown
- 2013-12-17 EA EA201591021A patent/EA029650B1/ru unknown
- 2013-12-27 AR ARP130105072A patent/AR094318A1/es not_active Application Discontinuation
- 2013-12-30 TW TW102148993A patent/TWI590819B/zh active
- 2013-12-30 UY UY0001035253A patent/UY35253A/es not_active Application Discontinuation
- 2013-12-30 JO JOP/2013/0390A patent/JO3483B1/ar active
-
2015
- 2015-06-16 TN TNP2015000275A patent/TN2015000275A1/fr unknown
- 2015-06-18 PH PH12015501402A patent/PH12015501402B1/en unknown
- 2015-06-24 IL IL239622A patent/IL239622B/en active IP Right Grant
- 2015-06-30 CL CL2015001881A patent/CL2015001881A1/es unknown
- 2015-07-14 ZA ZA2015/05057A patent/ZA201505057B/en unknown
-
2016
- 2016-03-14 US US15/069,118 patent/US9611205B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ712207A (en) | Tetrahydropyrrolothiazine compounds | |
| NZ779654A (en) | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs | |
| IN2014DN10670A (es) | ||
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| SI2892563T1 (sl) | Farmacevtski sestavki za zdravljenje alzheimerjeve bolezni | |
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| IN2015DN01023A (es) | ||
| WO2013040227A3 (en) | Therapeutic compounds | |
| PH12015501402A1 (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| MX361233B (es) | Inhibidores de hsp90 c-terminales. | |
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| PH12016502568B1 (en) | Novel heterocyclic compound | |
| HK1202452A1 (en) | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation | |
| MX2016008968A (es) | Compuestos organicos. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| GB201206984D0 (en) | New therapeutic use | |
| IN2013MU03838A (es) | ||
| WO2013121334A3 (en) | Agents for treating neurodegenerative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |